Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;28(11):2353-2363.
doi: 10.1038/s41591-022-02047-z. Epub 2022 Nov 10.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Justin Jee  1 , Emily S Lebow  1 , Randy Yeh  1 , Jeeban P Das  1 , Azadeh Namakydoust  1 , Paul K Paik  1   2 , Jamie E Chaft  1   2 , Gowtham Jayakumaran  1 , A Rose Brannon  1 , Ryma Benayed  1 , Ahmet Zehir  1 , Mark Donoghue  1 , Nikolaus Schultz  1 , Debyani Chakravarty  1 , Ritika Kundra  1 , Ramyasree Madupuri  1 , Yonina R Murciano-Goroff  1 , Hai-Yan Tu  1   3 , Chong-Rui Xu  1   3 , Andrés Martinez  1 , Clare Wilhelm  1 , Jesse Galle  1 , Bobby Daly  1   2 , Helena A Yu  1   2 , Michael Offin  1   2 , Matthew D Hellmann  1   2 , Piro Lito  1   2 , Kathryn C Arbour  1   2 , Marjorie G Zauderer  1   2 , Mark G Kris  1   2 , Kenneth K Ng  1   2 , Juliana Eng  1   2 , Isabel Preeshagul  1   2 , W Victoria Lai  1   2 , John J Fiore  1   2 , Afsheen Iqbal  1   2 , Daniela Molena  1   2 , Gaetano Rocco  1   2 , Bernard J Park  1   2 , Lee P Lim  4 , Mark Li  4 , Candace Tong-Li  5   6 , Madhawa De Silva  5 , David L Chan  5 , Connie I Diakos  5 , Malinda Itchins  5 , Stephen Clarke  5 , Nick Pavlakis  5 , Adrian Lee  5 , Natasha Rekhtman  1   2 , Jason Chang  1   2 , William D Travis  1   2 , Gregory J Riely  1   2 , David B Solit  1   2 , Mithat Gonen  1 , Valerie W Rusch  1   2 , Andreas Rimner  1   2 , Daniel Gomez  1   2 , Alexander Drilon  1   2 , Howard I Scher  1   2 , Sohrab P Shah  1 , Michael F Berger  1 , Maria E Arcila  1   2 , Marc Ladanyi  1   2 , Ross L Levine  1   2 , Ronglai Shen  1 , Pedram Razavi  1   2 , Jorge S Reis-Filho  1   2 , David R Jones  1   2 , Charles M Rudin  1   2 , James M Isbell  1   2 , Bob T Li  7   8
Affiliations

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Justin Jee et al. Nat Med. 2022 Nov.

Abstract

Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an international cohort of 1,127 patients with non-small-cell lung cancer and ctDNA-guided therapy. ctDNA detection was associated with shorter survival (hazard ratio (HR), 2.05; 95% confidence interval (CI), 1.74-2.42; P < 0.001) independently of clinicopathologic features and metabolic tumor volume. Among the 722 (64%) patients with detectable ctDNA, 255 (23%) matched to targeted therapy by ctDNA sequencing had longer survival than those not treated with targeted therapy (HR, 0.63; 95% CI, 0.52-0.76; P < 0.001). Genomic alterations in ctDNA not detected by time-matched tissue sequencing were found in 25% of the patients. These ctDNA-only alterations disproportionately featured subclonal drivers of resistance, including RICTOR and PIK3CA alterations, and were associated with short survival. Minimally invasive ctDNA profiling can identify heterogeneous drivers not captured in tissue sequencing and expand community access to life-prolonging therapy.

PubMed Disclaimer

Conflict of interest statement

J.J. has a patent licensed by MDSeq. A.N. reports serving as a one-time paid consultant for Bayer. P.K.P. receives compensation for consulting or advisory board participation from Bicara Therapeutics, Boehringer Ingelheim, EMD Serono, GlaxoSmithKline, Takeda Pharmaceuticals, WC Communications and Xencor and receives honoraria for participation in CME educational programs from PeerVoice, ACE Oncology Research to Practice, Clinical Care Options, Spring to Life and Touch Independent Medical Education. J.E.C. has served as a consultant for Astra Zeneca, Bristol-Myers Squib, Genentech, Merck, Flame Biosciences, Novartis, Regeneron-Sanofi, Guardant Health and Janssen and has received research funding to her institution from Astra Zeneca, Bristol-Myers Squib, Genentech and Merck. A.R.B. has stock ownership in Johnson & Johnson. R.B. reports a grant from Archer, honoraria for advisory board participation from Loxo oncology and speaking fees from Illumina. A.Z. has received speaking fees from Illumina. D.C. has consulted with/received honoraria from Pfizer, Loxo/Lilly Oncology, BridgeBio, FORE Therapeutics, Scorpion Therapeutics and Vividion Therapeutics. Y.R.M.-G. acknowledges receipt of training through an institutional K30 grant from the NIH (CTSA UL1TR00457). She has received funding from a Kristina M. Day Young Investigator Award from Conquer Cancer, the ASCO Foundation, funded by Charles M. Baum and Carol A. Baum. She reports travel, accommodation and expenses from AstraZeneca and honoraria from Virology Education. She acknowledges research funding to the institution from Loxo Oncology at Eli Lilly, Elucida Oncology, Taiho Oncology, Hengrui USA/Jiangsu Hengrui Pharmaceuticals and Endeavor Biomedicines. She acknowledges royalties from Rutgers University Press and Wolters Kluwer. H.-Y.T. has received academic travel support from Resolution Bioscience. C.X. has received honoraria from AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, Merck & Co., Novartis, Pfizer and Roche; has received research support from BeiGene and Hengrui Pharmaceutical; and has received reimbursement for travel and accommodation expenses from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, Merck & Co., Novartis, Pfizer and Roche. B.D. reports equity interest in Eli Lilly and Company, Roche and CVS Health and family member involvement with Eli Lilly and Company and CVS Health. H.A.Y. has consulted for AstraZeneca, Blueprint Medicine, Janssen Oncology, Cullinan and Daiichi. Her institution has received research funding for clinical trials from AstraZeneca, Daiichi, Pfizer, Novartis, Cullinan Oncology and Lilly. M.O. reports personal fees from PharmaMar, personal fees from Novartis, personal fees from Targeted Oncology, personal fees from Bristol-Myers Squibb, personal fees from Merck Sharp & Dohme, personal fees from Jazz Pharmaceuticals and personal fees from Astro Pharmaceuticals, outside the submitted work. M.D.H. reports grants from BMS and personal fees from Achilles, Adagene, Adicet, Arcus, AstraZeneca, Blueprint, BMS, DaVolterra, Eli Lilly, Genentech/Roche, Genzyme/Sanofi, Janssen, Immunai, Instil Bio, Mana Therapeutics, Merck, Mirati, Natera, Pact Pharma, Shattuck Labs and Regeneron, as well as equity options from Factorial, Immunai, Shattuck Labs and Arcus. A patent filed by Memorial Sloan Kettering related to the use of TMB to predict response to immunotherapy (PCT/US2015/062208) is pending and licensed by PGDx. P.L. is listed as an inventor on patent applications filed by MSKCC that describe approaches to treat KRAS or BRAF-mutant tumors. K.C.A. reports personal fees from AstraZeneca and nonfinancial support from Takeda and Novartis outside the submitted work. In the last 3 years, M.G.Z. has received consulting fees from Takeda, GlaxoSmithKline, Expert Connect, Aldeyra Therapeutics, Novocure and Atara and honoraria from Research to Practice, Medical Learning Institute and OncLive. Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis and Atara for research conducted by M.G.Z. M.G.Z. serves as chair of the board of directors of the Mesothelioma Applied Research Foundation, uncompensated. M.G.K. receives personal fees from Novartis, Sanofi-Genzyme, AstraZeneca, Pfizer, Janssen and Daiichi-Sankyo; received honoraria for participation in educational programs from WebMD, OncLive, Physicians Education Resources, Prime Oncology, Intellisphere, Creative Educational Concepts, Peerview, i3 Health, Paradigm Medical Communications, AXIS, Carvive Systems and AstraZeneca; received travel support from AstraZeneca, Pfizer and Genentech; and received editorial support from Hoffman La-Roche. Memorial Sloan Kettering has received research funding from the National Cancer Institute (USA), the Lung Cancer Research Foundation and Genentech Roche for research conducted by M.G.K. I.P. has consulted or served on the advisory boards of Pfizer, AstraZeneca, Blueprint Medicine, DavaOncology, Eli Lilly and Curio Science. W.V.L. receives institutional research funding from Daiichi Sankyo, Amgen and Abbvie and has been a compensated consultant for PharmaMar, G1 Therapeutics, AstraZeneca and Jazz Pharmaceuticals. D.M. is a consultant for AstraZeneca, Johnson & Johnson, Boston Scientific, Bristol Myers Squibb and Merck. G.R. receives royalties from Scanlan International. B.J.P. is a consultant for AstraZeneca. L.P.L. is an employee and shareholder of Agilent Technologies. M.L. is an employee and shareholder of Agilent Technologies. C.I.D. reports serving on the advisory board for Amgen and Ipsen, honoraria for Merck and academic travel support from Roche. M.I. reports serving on the advisory boards of Pfizer and Takeda; receiving honoraria from Roche, AstraZeneca, MSD, Bristol Myers Squibb, Pfizer, Takeda and Novartis; and travel support from Roche, AstraZeneca and MSD. S.C. reports advisory board fees from Roche and Astra Zeneca and travel support from Bristol Myers Squibb, outside the submitted work. N.P. has served on advisory boards or received personal honoraria from Boehringer Ingelheim, MSD, Merck, Bristol-Myers Squib, Astra Zeneca, Takeda, Pfizer, Roche, Novartis, Ipsen and Bayer and has received research funding to his institution from Bayer, Pfizer and Roche. A.L. reports personal fees and travel funding from Mundipharma/Helsinn, personal fees from Bayer and personal fees from Eisai. G.J.R. reports grants from National Institutes of Health/National Cancer Institute, has been an uncompensated consultant to Daiichi, Pfizer and Mirati and has institutional research support from Mirati, Takeda, Merck, Roche, Pfizer and Novartis. In addition, G.J.R. has pending patents US20170273982A1 and WO2017164887A8. D.B.S. has served as a consultant for/received honoraria from Loxo Oncology, Lilly Oncology, Pfizer, QED Therapeutics, Vivideon Therapeutics and Illumina. M.L. has received honoraria for advisory board participation from Merck, Astra-Zeneca, Bristol Myers Squibb, Blueprint Medicines, Janssen Pharmaceuticals, Takeda Pharmaceuticals, Lilly Oncology, LOXO Oncology, Bayer, ADC Therapeutics, Riken Genesis and Paige AI and research support from LOXO Oncology, Merus, and Helsinn Therapeutics. Marc Ladanyi reports honoraria for ad-hoc advisory board participation from Merck, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, and Lilly Oncology; and research support from LOXO Oncology, Merus and Helsinn Therapeutics. V.W.R. reports grants from Genelux, grants from Genentech, other from DaVinci Surgery, nonfinancial support from Bristol Myers Squibb and personal fees from NIH/Coordinating Center for Clinical Trials, outside the submitted work. A.R. reports grants from Varian Medical Systems, grants and personal fees from AstraZeneca, grants and personal fees from Merck, grants and personal fees from Boehringer Ingelheim, grants from Pfizer, personal fees from Research to Practice, personal fees from Cybrexa, personal fees from More Health and nonfinancial support from Philips/Elekta, outside the submitted work. D.G. reports grants from Varian, AstraZeneca, Merck and Bristol Myers Squibb and personal fees from Varia, AstraZeneca, Merck, US Oncology, Bristol Myers Squibb, Relfexion, WebMD, Vindico and Medscape and has served on the advisory board for AstraZeneca. A.D. has received honoraria or worked on the advisory boards of Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Remedica, ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX, Nuvalent, Merus, AXIS, Chugai Pharm and EPG Health; has received funding through his institution from Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho and PharmaMar; has received research support from Foundation Medicine; receives royalties from Wolters Kluwer; has received other support from Boehringer Ingelheim; has received food/beverage from Merck, Puma and Merus; and has received CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME and Clinical Care Options. H.I.S. reports the following support: compensated consultant/advisor to Ambry Genetics, Konica Minolta, Bayer, Pfizer, Sun Pharmaceuticals and WCG Oncology; uncompensated consultant/advisory to Amgen, ESSA Pharma, Janssen Research & Development, Janssen Biotech and Sanofi Aventis; he has received research funding (to his institution) from Epic Sciences, Illumina, Janssen, Menarini Silicon Biosystems, Prostate Cancer Foundation and ThermoFisher; intellectual property rights from BioNTech, Elucida Oncology, MaBVAX and Y-mAbs Therapeutics; and nonfinancial support from Amgen, Asterias Biotherapeutics, Bayer, ESSA Pharma, Menarini Silicon Biosystems, Phosplatin, Pfizer, Prostate Cancer Foundation and WCG Oncology. S.P.S. is a shareholder and consultant of Canesia Health. M.F.B. reports a consulting/advisory role with PetDx and Eli Lilly; research support from Grail; and a patent pending related to cfDNA profiling. R.L. is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Syndax. Zentalis, Ajax, Bakx, Auron, Prelude, C4 Therapeutics and Isoplexis for which he receives equity support. He receives research support from Ajax and Abbvie and has consulted for Incyte, Janssen, Morphosys and Novartis. He has received honoraria from Astra Zeneca and Kura for invited lectures and from Gilead for grant reviews. P.R. received institutional grant/funding from Grail, Illumina, Novartis, Epic Sciences and ArcherDx and consultation/ad board/honoraria from Novartis, Foundation Medicine, AstraZeneca, Epic Sciences, Inivata, Natera and Tempus. J.R.-F. is a paid consultant of Goldman Sachs, Paige.AI and REPARE Therapeutics, a member of the scientific advisory board of Goldman Sachs, Paige.AI and Volition RX, and an ad hoc member of the scientific advisory board of Roche, Genentech, Roche Tissue Diagnostics, Ventana, Novartis, InVicro and GRAIL. D.R.J. serves as a consultant for AstraZeneca and Merck. C.M.R. reports personal fees from AbbVie, Amgen, Ascentage, AstraZeneca, Bicycle, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Jansen, Jazz, Lilly/Loxo, Pfizer, PharmaMar, Syros, Vavotek, Bridge Medicines and Harpoon Therapeutics, outside the submitted work. J M.I. reports equity in LumaCyte and has served as an uncompensated member of a steering committee for Genentech. B.T.L. has served as an uncompensated advisor and consultant to Amgen, Genentech, Boehringer Ingelheim, Lilly, AstraZeneca and Daiichi Sankyo. He has received research grants to his institution from Amgen, Genentech, AstraZeneca, Daiichi Sankyo, Lilly, Illumina, GRAIL, Guardant Health, Hengrui Therapeutics, MORE Health and Bolt Biotherapeutics. He has received academic travel support from MORE Health and Jiangsu Hengrui Medicine. He is an inventor on two institutional patents at Memorial Sloan Kettering (US62/685,057, US62/514,661) and has intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press. The remaining authors declare no competing interests.

Figures

Extended Data Fig. 1 |
Extended Data Fig. 1 |. Turnaround time of plasma and tissue sequencing.
Boxplots showing median (center) +/−25%ile (boxes) and 95%ile (whiskers) of turnaround time for liquid biopsy (MSK-ACCESS and ctDx Lung, N independent samples = 2,162) and tissue (MSK-IMPACT, N independent samples = 612) sequencing from date of blood collection. Tissue start time is the date of white blood cell control collection. The turnaround time for plasma ctDNA sequencing was significantly faster than for tissue sequencing (*two-sided Mann-Whitney U, p < 0.001).
Extended Data Fig. 2 |
Extended Data Fig. 2 |. Correlates of ctDNA alteration levels.
Histograms showing the proportion of patients with either number of ctDNA alterations or maximum mutation variant allele frequency (VAF) per sample. P-values are from Mann-Whitney U tests or Kruskal-Wallis tests for histologic subgroups. Raw VAFs of zero are set to the minimum value of the log axis.
Extended Data Fig. 3 |
Extended Data Fig. 3 |. Survival of patients without tissue sequencing matched to targeted therapy by ctDNA.
Kaplan-Meier survival curves for patients without tissue sequencing matched or not matched to targeted therapy. Number at risk in each category is adjusted for left truncation and time-dependent nature of targeted therapy variables.
Fig. 1 |
Fig. 1 |. Status of enrolled patients.
CONSORT diagram showing excluded patients as well as status of ctDNA/tissue sequencing and targeted therapy during the study for included patients.
Fig. 2 |
Fig. 2 |. ctDNA alterations and OS.
a, Kaplan–Meier survival curves for patients with versus without ctDNA detected (defined by alteration presence). Number at risk adjusted for study/variable entry time. b, Forest plots comparing patients with versus without ctDNA alterations in the listed subgroups (median OS and the number of independent patients in both the ctDNA+ and ctDNA− arms are given in Supplementary Table 3). Error bars represent 95% CI. EGFR, KRAS and TP53 subgroups compare patients with alterations in these genes in ctDNA to those with alterations in these genes in tumor tissue only. c, Multivariate Cox proportional hazards model with the listed variables in patients with time-matched PET imaging. ‘Targeted’, treated with targeted therapy. Error bars represent 95% CI. Total cohort size and number of independent patients in each variable arm are listed in the figure (n). d, Scatterplot showing the relationship between ctDNA maximum VAF and MTV among segmented patients with treatment-naive adenocarcinoma. Values of zero are set to the minimum of the respective log axes. R and P values from two-sided Spearman’s correlation coefficient (P = 2 × 10−6). Representative examples of discordance between MTV and VAF are shown. e. Kaplan–Meier survival curves for patients stratified by MTV and ctDNA detection. Number at risk adjusted for study/variable entry time. f, Multivariate Cox proportional hazards model with log10(MTV) as a continuous variable and ctDNA detection. Error bars represent 95% CI. n, number of independent patients in the total analysis.
Fig. 3 |
Fig. 3 |. Clinical utility of ctDNA and tissue sequencing.
a, Kaplan–Meier survival curves for patients matched to targeted therapy by ctDNA, not treated with targeted therapy but ctDNA+, matched to targeted therapy by tissue only and not treated with targeted therapy and ctDNA−. Number at risk adjusted for study/variable entry time. P values are from a two-sided Cox proportional hazards model and were not adjusted for multiple hypotheses. b, Number of patients matched to a given molecular target by ctDNA and tissue sequencing or tissue sequencing only.
Fig. 4 |
Fig. 4 |. ctDNA mutations not detected on time-matched tissue sequencing (MSK-IMPACT).
a, Kaplan–Meier survival curves for patients without ctDNA alterations (black) or with ctDNA-only alterations (purple), compared by two-sided Cox proportional hazards model (P = 1 × 10−5). b, Forest plots comparing patients with ctDNA-only alterations versus those with matched ctDNA–tissue alterations only in the listed subgroups (the median OS and number of independent patients in each arm are given in Supplementary Table 8). Error bars represent 95% CI. c,d, Scatterplots of mutations (c) and CNAs (d) detected in ctDNA. Red dots correspond to ctDNA-only alterations. The y axis in d shows CNA levels calculated algorithmically from tissue MSK-IMPACT. Histograms at the top and right show the density of points of each category along the respective axis. Raw values of zero were set to the minimum value of the log axis.
Fig. 5 |
Fig. 5 |. Correlates of plasma–tissue divergence.
a,b, Boxplots showing cTF for patients with (n = 102 independent patients) and without (n = 30 independent patients) ctDNA-only alterations (two-sided Mann–Whitney U test, P = 0.5) (a) and MTV on time-matched PET imaging (segmented independent patients only, n = 129) for patients without ctDNA (n = 41), with tissue-matched ctDNA only (n = 62) and with ctDNA-only alterations (n = 25) (b). Boxes denote medians ±IQRs. Whiskers denote 1.5 times IQRs. P values are from two-sided Mann–Whitney U tests (P value for tissue-matched versus no ctDNA, 8 × 10−10; ctDNA-only versus tissue-matched, 1 × 10−5). c, Top, scatterplot showing the proportion of patients with an oncogenic driver in a given gene as detected in either tissue (±ctDNA) or in ctDNA only (that is, not in tissue). Pearson’s two-sided P value = 1 × 10−5. Bottom, fraction of the total number of patients with an oncogenic driver in the indicated gene detected only in ctDNA. Center points are fractions; whiskers are binomial 95% CI. Only genes with at least 10 patients possessing such a driver by either method are shown. ANOVA, P value = 4 × 10−13. d, Multivariate Cox proportional hazards model with the listed variables. Oncogenic driver gene alterations refer to those found in either tissue or ctDNA.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kris MG et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998–2006 (2014). - PMC - PubMed
    1. Howlader N et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med 383, 640–649 (2020). - PMC - PubMed
    1. Pasche B & Grant SC Non-small cell lung cancer and precision medicine a model for the incorporation of genomic features into clinical trial design. JAMA 311, 1975 (2014). - PubMed
    1. Bruno DS et al. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC). J. Clin. Oncol 39, 9005 (2021).
    1. Robert NJ et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. J. Clin. Oncol. 39, 9004 (2021).

Publication types

MeSH terms